Recombinant CEACAM5 (Tusamitamab Biosimilar) 抗体
适用: 人
ELISA, FACS, BLI, Func, SPR
宿主: Human
Monoclonal
unconjugated
Recombinant Antibody
-
- 抗原
- CEACAM5 (Tusamitamab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
-
Human
- Expression System
- CHO Cells
-
克隆类型
- 单克隆
-
标记
- This CEACAM5 (Tusamitamab Biosimilar) antibody is un-conjugated
- 应用范围
- ELISA, Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), Functional Studies (Func), Surface Plasmon Resonance (SPR)
- 原理
- Anti-CEACAM5 / CEA / CD66e Reference Antibody (tusamitamab)
- 序列
- EVQLQESGPG LVKPGGSLSL SCAASGFVFS SYDMSWVRQT PERGLEWVAY ISSGGGITYA PSTVKGRFTV SRDNAKNTLY LQMNSLTSED TAVYYCAAHY FGSSGPFAYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG,DIQMTQSPAS LSASVGDRVT ITCRASENIF SYLAWYQQKP GKSPKLLVYN TRTLAEGVPS RFSGSGSGTD FSLTISSLQP EDFATYYCQH HYGTPFTFGS GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
- 产品特性
- Anti-CEACAM5 / CEA / CD66e Reference Antibody (tusamitamab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
- 纯度
- >95 %
- 亚型
- IgG1
-
anti-CEACAM5 (Tusamitamab Biosimilar) (Glu239Asp-Mutant), (Met241Leu-Mutant) antibody
Research Grade 适用: 人 ELISA, FACS 宿主: 小鼠 Chimeric unconjugated
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 说明
-
Therapeutic Agents by Target and Mechanism: CEACAM5 antagonist
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 浓度
- 1 mg/mL
- 缓冲液
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
- 储存条件
- 4 °C,-80 °C
- 储存方法
- +4°C,-80°C
-
- 抗原
- CEACAM5 (Tusamitamab Biosimilar)
- 物质类
- Biosimilar
- 分子量
- 145.5 kDa
- UniProt
- P06731
-
You are here:
